Clinical applications and advances of positron emission tomography with fluorine-18- fluorodeoxyglucose (18F-FDG) in the diagnosis of liver neoplasms

Postgraduate Medical Journal

Volumn 84, Issue 991, 2008, Pages 246-251

  He, Y X ^a   Guo, Q Y ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; IRINOTECAN; PENTETREOTIDE IN 111;

BILE DUCT CARCINOMA; CANCER CELL; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CELL DIFFERENTIATION; CHEMOEMBOLIZATION; CLINICAL EVALUATION; CRYOSURGERY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG METABOLISM; DRUG UPTAKE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIOFREQUENCY ABLATION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR CELL;

CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 45249117926     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2007.066589     Document Type: Review

References (55)

1. Gambhir S, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Warburg O, Wind F, Negelein E. On the metabolism of tumors in the body. In: Warburg O, ed. The metabolism of tumors. London: Constable, 1930:254-70.
4. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Bioli 2001;18:247-56.
5. Higashi T, Saga T, Nakamoto Y, et al. Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer. J Nucl Med 2002;43:173-180.
6. Haberkorn U, Ziegler SI, Oberdorfer F, et al. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl Med Biol 1994;21:827-34.
7. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13(2 Pt 1):427-33.
8. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004;45:1431-4.
9. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellar carcinoma. J Hepatol 2000;32:792-7.
10. Iwata Y, Shiomi S, Sasaki N, et al. Clinical usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in the diagnosis of liver tumors. Ann Nucl Med 2000;14:121-6.
11. Zimmerman RL, Burke M, Young NA, et al. Diagnostic utility of Glut-1 and CA 15-3 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer 2002;96:53-7.
12. Roh MS, Jeong JS, Kim YH, et al. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology 2004;51:1315-8.
13. Yang SH, Suh KS, Lee HW, et al. The role of (18) F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-60.
14. Hatano E, Ikai I, Higashi T, et al. Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006;30:1736-41.
15. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-80.
16. Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma. Korean J Hepatol 2004;10:279-87.
17. Shang JB, Li YH, Liu FY, et al. 18F-Fluorodeoxyglucose uptake in hepatocellular carcinoma on positron emission tomography correlates with alpha-fetoprotein. Di Yi Jun Yi Da Xue Xue Bao 2004;24:697-9.
18. Lee JD, Yun M, Lee JM, et al. Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. Eur J Nucl Med Mol Imaging 2004;31:1621-30.
19. Ho CL, Yu SC, Yeung DW. [11C]-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-21.
20. Li S, Beheshti M, Peck-Radosavljevic M, et al. Comparison of (11) C-acetate positron emission tomography and (67) aallium citrate scintigraphy in patients with hepatocellular carcinoma. Liver Int 2006;26:920-7.
21. Lenzo NP, Anderson J, Campbell A, et al. Fluoromethylcholine PET in recurrent multifocal hepatoma. Australas Radiol 2007;51(Suppl):B 299-302.
22. Rabinowitz I, Telepak R, Lee FC. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Clin Nucl Med 2002;27:499-502.
23. Delbeke D, Martin WH, Sandler MP, et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-5.
24. Kate T, Tsukamoto E, Kuge Y, et al. Clinical role of (18)F-FDG-PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002;29:1047-54.
25. Kim YJ, Yun M, Lee WJ, et al. Usefulness of 18FFDG-PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003;30:1467-72.
26. Fritscher-Ravens A, Bohuslavizki KH, Broering DC, et al. FDG-PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 2001;22:1277-85.
27. Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18) F-FDG uptake. J Nucl Med 2005;46:1753-9.
28. Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130:266-72.
29. Hustinx R, Paulus P, Jacquet N, et al. Clinical evaluation of whole-body 18F-fluorodeoxyglucose positron emission tomography in the detection of liver metastases. Ann Oncol 1998;9:397-401.
30. Arulampalam TH, Francis DL, Visvikis D, et al. FDGPET for the pre-operative evaluation of colorectal liver metastases. Eur J Surg Oncol 2004;30:286-91.
31. Wiering B, Ruers TJ, Krabbe PF, et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007;14:818-26.
32. Yang M, Martin DR, Karabulut N, et al. Comparison of MR and PET imaging for the evaluation of liver metastases. J Magn Reson Imaging 2003;17:343-9.
33. Bohm B, Voth M, Geoghegan J, et al. Impact of positron emission tomography on strategy in liver resection for primary and secondary liver tumors. J Cancer Res Clin Oncol 2004;130:266-72.
34. Kinkel K, Lu Y, Both M, et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 2002;224:748-56.
35. Grobmyer SR, Wang L, Gonen M, et al. Perihepatic lymph node assessment in patients undergoing partial hepatectomy for malignancy. Ann Surg 2006;244:260-4.
36. Goshen E, Davidson T, Zwas ST, et al. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol Cancer Res Treat 2006;5:37-43.
37. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32:153-62.
38. Joyce DL, Wahl RL, Patel PV, et al. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg 2006;141:1220-6.
39. Wiering B, Krabbe PF, Dekker HM, et al. The role of FDG-PET in the selection of patients with colorectal liver metastases. Ann Surg Oncol 2007;14:771-9.
40. Takahashi S, Kuroki Y, Nasu K, et al. Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy. Anticancer Res 2006;26:4705-11.
41. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2000;214:761-8.
42. Jiao LR, Szyszko T, Al-Nahhas A, et al. Clinical and imaging experience with yttrium-90 microspheres in the management of unresectable liver tumours. Eur J Surg Oncol 2007;33:597-602.
43. Miller FH, Keppke AL, Reddy D, et al. Response of liver metastases after treatment with yttrium-90 microspheres: role of size, necrosis, and PET. AJR Am J Roentgenol 2007;188:776-83.
44. Tehranipour N, Al-Nahhas A, Canelo R, et al. Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nucl Med 2007;32:371-4.
45. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radiofrequency ablation of medium and large lesions. Radiology 2001;218:918-9.
46. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;84:215-23.
47. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;20:4453-8.
48. Anderson GS, Brinkmann F, Soulen MC, et al. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003;28:192-7.
49. Amthauer H, Denecke T, Hildebrandt B, et al. Evaluation of patients with liver metastases from colorectal cancer for locally ablative treatment with laser induced thermotherapy. Impact of PET with 18F-fluorodeoxyglucose on therapeutic decisions. Nuklearmedizin 2006;45:177-84.
50. Zhao M, Wu PH, Zeng YX, et al. Evaluating efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation on patients with hepatocellular carcinoma by 18FDG-PET/CT. Ai Zheng 2005;24:1118-23.
51. Myers R. The biological application of small animal PET imaging. Nucl Med Biol 2001;28:585-93.
52. Chatziioannou AF. Molecular imaging of small animals with dedicated PET tomographs. Eur J Nucl Med Mol Imaging 2002;29:98- 114.
53. Tatsumi M, Nakamoto Y, Traughber B, et al. Initial experience in small animal tumor imaging with a clinical positron emission tomography/computed tomography scanner using 2-[F-18] fluoro-2-deoxy-D-glucose. Cancer Res 2003;63:6252-7.
54. Stewart EE, Chen X, Hadway J, et al. Correlation between hepatic tumor blood flow and glucose utilization in a rabbit liver tumor model. Radiology 2006;239:740-50.
55. Ishiwata K, Liu HY, Teramoto K, et al. Tumor viability evaluation by positron emission tomography with [18F] FDG in the liver metastasis rat model. Ann Nucl Med 2006;20:463-9.